64 related articles for article (PubMed ID: 7627269)
1. A single missense mutation in codon 918 of the RET proto-oncogene in sporadic medullary thyroid carcinomas.
Maeda S; Namba H; Takamura N; Tanigawa K; Takahashi M; Noguchi S; Nagataki S; Kanematsu T; Yamashita S
Endocr J; 1995 Apr; 42(2):245-50. PubMed ID: 7627269
[TBL] [Abstract][Full Text] [Related]
2. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.
Kodama Y; Asai N; Kawai K; Jijiwa M; Murakumo Y; Ichihara M; Takahashi M
Cancer Sci; 2005 Mar; 96(3):143-8. PubMed ID: 15771616
[TBL] [Abstract][Full Text] [Related]
3. Presence of aberrant transcripts of ret proto-oncogene in a human papillary thyroid carcinoma cell line.
Ishizaka Y; Itoh F; Tahira T; Ikeda I; Ogura T; Sugimura T; Nagao M
Jpn J Cancer Res; 1989 Dec; 80(12):1149-52. PubMed ID: 2516841
[TBL] [Abstract][Full Text] [Related]
4.
Zhang HF; Huang SL; Wang WL; Zhou YQ; Jiang J; Dai ZJ
World J Clin Cases; 2024 May; 12(15):2627-2635. PubMed ID: 38817239
[TBL] [Abstract][Full Text] [Related]
5. RET proto-oncogene genotyping using unlabeled probes, the masking technique, and amplicon high-resolution melting analysis.
Margraf RL; Mao R; Highsmith WE; Holtegaard LM; Wittwer CT
J Mol Diagn; 2007 Apr; 9(2):184-96. PubMed ID: 17384210
[TBL] [Abstract][Full Text] [Related]
6. Timing and Ideal Patient for an Appropriate Search for Somatic
Matrone A; Prete A; Gambale C; Elisei R
JCO Precis Oncol; 2024 May; 8():e2400017. PubMed ID: 38709990
[TBL] [Abstract][Full Text] [Related]
7. Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers.
A T; F S; G P; M B
Curr Genomics; 2011 Dec; 12(8):618-25. PubMed ID: 22654561
[TBL] [Abstract][Full Text] [Related]
8. Mutational activation of the MAP3K8 protooncogene in lung cancer.
Clark AM; Reynolds SH; Anderson M; Wiest JS
Genes Chromosomes Cancer; 2004 Oct; 41(2):99-108. PubMed ID: 15287022
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of the p53 gene is not required for tumorigenesis of medullary thyroid carcinoma or pheochromocytoma.
Yana I; Nakamura T; Shin E; Karakawa K; Kurahashi H; Kurita Y; Kobayashi T; Mori T; Nishisho I; Takai S
Jpn J Cancer Res; 1992 Nov; 83(11):1113-6. PubMed ID: 1483923
[TBL] [Abstract][Full Text] [Related]
10. Rapid and long-lasting response to selpercatinib of paraneoplastic Cushing's syndrome in medullary thyroid carcinoma.
Sitbon M; Chou P; Bengaly S; Poirot B; Laloi-Michelin M; Deville L; Pachev A; Kowo-Bille A; Dumont C; Chougnet CN
Eur Thyroid J; 2022 Dec; 11(6):. PubMed ID: 36069795
[TBL] [Abstract][Full Text] [Related]
11. Multiple endocrine neoplasia 2A presenting in a family with a history of Hirschprung's disease.
Johns AM; Vuong AH; Hassan OA; Randle RW; Gorris MA
Oxf Med Case Reports; 2021; 2021(11-12):omab122. PubMed ID: 34987852
[TBL] [Abstract][Full Text] [Related]
12. Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease Aggressiveness.
Shirali AS; Hu MI; Chiang YJ; Graham PH; Fisher SB; Sosa JA; Perrier N; Brown S; Holla VR; Dadu R; Busaidy N; Sherman SI; Cabanillas M; Waguespack SG; Zafereo ME; Grubbs EG
J Endocr Soc; 2024 Apr; 8(6):bvae048. PubMed ID: 38660141
[TBL] [Abstract][Full Text] [Related]
13. Mutation screening of RET proto-oncogene in a family with medullary thyroid carcinoma, marfanoid habitus and pheochromocytoma; from clinically MEN2B to genetically MEN2A syndrome.
Hasani-Ranjbar S; Amoli MM
Endocrine; 2012 Jan; ():. PubMed ID: 22290487
[No Abstract] [Full Text] [Related]
14. The p.G534E variant of
Kowalik A; Gąsior-Perczak D; Gromek M; Siołek M; Walczyk A; Pałyga I; Chłopek M; Kopczyński J; Mężyk R; Kowalska A; Góźdź S
Oncotarget; 2017 Aug; 8(35):58304-58308. PubMed ID: 28938557
[TBL] [Abstract][Full Text] [Related]
15. Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade.
Watson AJ; Hopkins GV; Hitchin S; Begum H; Jones S; Jordan A; Holt S; March HN; Newton R; Small H; Stowell A; Waddell ID; Waszkowycz B; Ogilvie DJ
F1000Res; 2016; 5():1005. PubMed ID: 27429741
[TBL] [Abstract][Full Text] [Related]
16. Correction to "Design and Synthesis of Novel Thieno[3,2-
La Monica G; Pizzolanti G; Baiamonte C; Bono A; Alamia F; Mingoia F; Lauria A; Martorana A
ACS Omega; 2023 Dec; 8(50):48582. PubMed ID: 38144131
[TBL] [Abstract][Full Text] [Related]
17. Response to "Sporadic noninvasive medullary thyroid neoplasm: A desmoplasia-negative unifocal nonmetastatic tumor cured by hemithyroidectomy".
Papavramidis T; Chorti A; Cheva A
Surgery; 2024 Apr; ():. PubMed ID: 38575430
[No Abstract] [Full Text] [Related]
18. The finding of a somaticdeletion in RET exon 15 clarified the sporadic nature of amedullary thyroid carcinoma suspected to be familial.
Oriola J; Halperin I; Rivera-Fillat F; Donis-Keller H
J Endocrinol Invest; 2002 Jan; 25(1):25-31. PubMed ID: 11883863
[TBL] [Abstract][Full Text] [Related]
19. Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type.
Uchino S; Noguchi S; Yamashita H; Sato M; Adachi M; Yamashita H; Watanabe S; Ohshima A; Mitsuyama S; Iwashita T; Takahashi M
Jpn J Cancer Res; 1999 Nov; 90(11):1231-7. PubMed ID: 10622534
[TBL] [Abstract][Full Text] [Related]
20. Somatic mutations in the RET protooncogene in Japanese and Chinese sporadic medullary thyroid carcinomas.
Shan L; Nakamura M; Nakamura Y; Utsunomiya H; Shou N; Jiang X; Jing X; Yokoi T; Kakudo K
Jpn J Cancer Res; 1998 Sep; 89(9):883-6. PubMed ID: 9818022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
